Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467634 | 0.88 | ACVR1 (0.41) | HRH4HRH3FLT3 | |
| SCHEMBL30090827 | 0.88 | ACVR1 (0.41) | HRH4HRH3FLT3 | |
| SCHEMBL27767958 | 0.83 | HRH3 (0.42) | HRH3 | |
| SCHEMBL18009414 | 0.83 | KDM4E (0.56) | HRH4HRH3HTR3AFLT3KDM4E | |
| SCHEMBL27767974 | 0.81 | ADORA2A (0.39) | FLT3 | |
| SCHEMBL28805725 | 0.79 | L3MBTL3 (0.46) | HRH3 | |
| SCHEMBL28997652 | 0.78 | HRH3 (0.42) | HRH3MAP4K4 | |
| SCHEMBL27901888 | 0.78 | L3MBTL3 (0.44) | HRH3KMT2A | |
| SCHEMBL27919685 | 0.78 | L3MBTL3 (0.44) | HRH3KMT2A | |
| SCHEMBL28802365 | 0.77 | CASP1 (0.39) | FLT3KDM4EGAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101622246-B | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-30 | — | — | CN | claimed |
| CN-101622248-B | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2013-04-17 | — | — | CN | claimed |
| CN-101622246-A | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | claimed |
| CN-101622248-A | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | claimed |
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-101622246-B | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-30 | — | — | CN | disclosed |
| CN-101622248-B | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2013-04-17 | — | — | CN | disclosed |
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| CN-101622248-A | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | disclosed |
| CN-101622246-A | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | disclosed |